Abstract
The consequences of chronic hepatitis B virus infection include hepatocellular carcinoma and liver cirrhosis. Effective antiviral therapy in patients with hepatitis B with advanced liver disease with viral suppression and sustained HBeAg seroconversion (where applicable) may abort hepatic decompensation, diminish hepatocellular risk, and reduce the risk of viral recurrence after transplantation. Overt hepatic decompensation is an indication for referral to a transplant center.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 477-493 |
| Number of pages | 17 |
| Journal | Clinics in liver disease |
| Volume | 14 |
| Issue number | 3 |
| DOIs | |
| State | Published - Aug 1 2010 |
Keywords
- Antiviral therapy
- Cirrhosis
- End-stage liver disease
- Hepatitis B
- Liver transplantation
ASJC Scopus subject areas
- Hepatology
Fingerprint Dive into the research topics of 'Management of end-stage liver disease in chronic hepatitis B'. Together they form a unique fingerprint.
Cite this
Tan, H. H., & Martin, P. (2010). Management of end-stage liver disease in chronic hepatitis B. Clinics in liver disease, 14(3), 477-493. https://doi.org/10.1016/j.cld.2010.05.006